We are live on
!
Find out more
HMC
Harvard Management Company Portfolio holdings
AUM
$1.82B
1-Year Est. Return
26.23%
This Fund
S&P 500
This Quarter
Est. Return
+14.38%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$1.74B
AUM Growth
-$52.1M
(-2.9%)
Cap. Flow
-$131M
Cap. Flow
% of AUM
-7.55%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
43
New
5
Increased
3
Reduced
12
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$315M |
| 2 |
DaVita
DVA
|
+$48.4M |
| 3 |
Recursion Pharmaceuticals
RXRX
|
+$44.7M |
| 4 |
Meta Platforms (Facebook)
META
|
+$35.2M |
| 5 |
Affirm
AFRM
|
+$30.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intercontinental Exchange
ICE
|
+$158M |
| 2 |
Adobe
ADBE
|
+$155M |
| 3 |
Royalty Pharma
RPRX
|
+$152M |
| 4 |
Microsoft
MSFT
|
+$61.7M |
| 5 |
Salesforce
CRM
|
+$34.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.04% |
| 2 | Technology | 25.62% |
| 3 | Consumer Discretionary | 12.12% |
| 4 | Communication Services | 10.39% |
| 5 | Financials | 6.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
iShares Core S&P Small-Cap ETF
IJR
$109B
| $5.7M | 0.33% |
50,474
+170
| +0.3% | +$19K |
|
27
Fulcrum Therapeutics
FULC
$273M
| $4.3M | 0.25% |
410,714
| – | – |
|
28
Vanguard FTSE Emerging Markets ETF
VWO
$121B
| $4.01M | 0.23% |
73,804
-6,697
| -8% | -$357K |
|
|
PRDS
29
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $4M | 0.23% |
400,000
| – | – |
|
30
iShares Core S&P Mid-Cap ETF
IJH
$122B
| $3.41M | 0.2% |
63,415
-17,230
| -21% | -$930K |
|
31
Dianthus Therapeutics
DNTH
$5.84B
| $3.25M | 0.19% |
20,788
| – | – |
|
32
Pinduoduo
PDD
$126B
| $3.24M | 0.19% |
25,493
-16,997
| -40% | -$2.21M |
|
33
Seres Therapeutics
MCRB
$46.8M
| $3.15M | 0.18% |
6,592
| – | – |
|
|
DBTX
34
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $2.83M | 0.16% |
328,798
| – | – |
|
35
Dyne Therapeutics
DYN
$4.7B
| $2.26M | 0.13% |
107,252
| – | – |
|
36
Disc Medicine
IRON
$2.96B
| $1.62M | 0.09% |
8,333
| – | – |
|
|
NCNA
37
NuCana
NCNA
$5.49M
| $1.07M | 0.06% |
77
-121
| -61% | -$2.13M |
|
38
Quince Therapeutics
QNCX
$22.9M
| $156K | 0.01% |
+15
| New | +$126K |
|
|
39
Adobe
ADBE
$99.5B
| – | – |
-326,100
| Closed | -$155M |
|
|
40
Salesforce
CRM
$151B
| – | – |
-164,622
| Closed | -$34.9M |
|
|
DADA
41
DELISTED
Dada Nexus
DADA
| – | – |
-49,887
| Closed | -$1.35M |
|
|
42
Microsoft
MSFT
$3.45T
| – | – |
-261,792
| Closed | -$61.7M |
|
43
Roblox
RBLX
$25.4B
| – | – |
-197,642
| Closed | -$12.8M |
|
Similar funds
DWT
MCC
ST
SI
WIC
GC
RHJA
KAM
Harvard Management Company's Q2 2021 Portfolio in Review
As of Q2 2021, Harvard Management Company held 43 positions worth $1.74B, down 2.9% from $1.79B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Harvard Management Company withdrew a net $131M in Q2 2021, closing 5 positions and reducing 12 holdings. Its most notable exit was Adobe, an estimated $155M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Harvard Management Company opened a new position in Apple worth $333M.
- Harvard Management Company's largest Q2 2021 buy was Apple: 2,434,903 shares worth $333M.
- Harvard Management Company added most to Meta Platforms (Facebook) in Q2 2021, an estimated $35.2M increase.
- Harvard Management Company's biggest Q2 2021 reduction was Intercontinental Exchange, cutting an estimated $158M.
- Harvard Management Company fully exited Adobe in Q2 2021, selling an estimated $155M.
- Harvard Management Company's ten largest holdings make up 82% of its $1.74B portfolio in Q2 2021.
- Harvard Management Company opened 5 new positions and closed 5 in Q2 2021.
- Harvard Management Company's portfolio value fell 2.9% quarter-over-quarter to $1.74B.
Based on Harvard Management Company's 13F filing for Q2 2021, filed 13 Aug 2021.